

BUMRUNGRAD HOSPITAL
THAILAND / HEALTHCARE

BH TB

BUY

UNCHANGED

ต้อนรับนักท่องเที่ยวเชิงสุขภาพกลับโรงพยาบาล

- รายได้ผู้ป่วยต่างชาติใน 1Q22 กระโดดเพิ่ม 28% q-q คิดเป็น 73% ของระดับก่อน Covid; ไม่เม้นต์จะต่อเนื่องไปตลอดปี 2022
- คาดกำไรปกติปี 2022 จะเพิ่ม 114% เป็น 2.7 พัน ลบ. พร้อม Upside จากการฟื้นตัวที่เร็วเกินคาดของผู้ป่วยต่างชาติ
- คงแนะนำซื้อ; ปรับการประเมินมูลค่าไปในปี 2023 (DCF)

TARGET PRICE	THB205.00
CLOSE	THB161.50
UP/DOWNSIDE	+26.9%
PRIOR TP	THB190.00
CHANGE IN TP	+7.9%
TP vs CONSENSUS	+16.8%

KEY STOCK DATA

YE Dec (THB m)	2021	2022E	2023E	2024E
Revenue	12,460	15,969	19,841	21,249
Net profit	1,216	2,731	4,199	4,636
EPS (THB)	1.53	3.43	5.28	5.83
vs Consensus (%)	-	(0.1)	15.2	11.7
EBITDA	2,613	4,483	6,264	6,879
Core net profit	1,274	2,731	4,199	4,636
Core EPS (THB)	1.60	3.43	5.28	5.83
Chg. In EPS est. (%)	-	-	-	-
EPS growth (%)	6.2	114.4	53.8	10.4
Core P/E (x)	100.9	47.1	30.6	27.7
Dividend yield (%)	2.0	2.0	2.0	2.0
EV/EBITDA (x)	47.1	27.3	19.1	17.0
Price/book (x)	7.4	7.4	6.7	6.1
Net debt/Equity (%)	(33.3)	(37.1)	(47.7)	(55.5)
ROE (%)	7.1	15.7	23.0	23.0

ฟื้นตัวใน 1Q22 จากตลาดตะวันออกกลางและอินโดจีน

ในที่ประชุมนักวิเคราะห์เมื่อวันที่ 6 พ.ค. 22 ผู้บริหารของ BH ได้ให้รายละเอียดเพิ่มเติมเกี่ยวกับกำไรปกติที่อยู่ในระดับสูงใน 1Q22 กำไรดังกล่าวเพิ่มขึ้น 640% y-y และ 9% q-q โดยมีปัจจัยหลักที่สนับสนุนอยู่ที่รายได้สุทธิจากผู้ป่วยต่างชาติ ซึ่งกระโดดเพิ่ม 28% q-q จากรายได้จากผู้ป่วยตะวันออกกลาง (+19% q-q) และอินโดจีน (+37% q-q) ด้วยเหตุดังกล่าวรายได้ผู้ป่วยต่างชาติฟื้นตัวเป็น 73% ของระดับก่อน Covid (เทียบกับ 47% ในปี 2021) ในขณะที่รายได้จากผู้ป่วยชาวไทยลดลง 7% q-q จากความต้องการที่น้อยลงที่ลดลง จำนวนวันทำงานที่ลดลง และผลกระทบจากสายพันธุ์ Omicron อย่างไรก็ตามรายได้ดังกล่าวยังสูงกว่าระดับก่อน Covid อยู่ 19%

การผ่อนคลายข้อบังคับการเดินทางของไทยช่วยหนุนการฟื้นตัว


โดยปกติ 2Q เป็นช่วงที่แย่ที่สุดของ BH เนื่องจากมีวันหยุดยาวและตัวเลขผู้ป่วยจากตะวันออกกลางจะลดลงเนื่องจากอยู่ในช่วงรอมฎอน อย่างไรก็ตามเราเชื่อว่าการผ่อนคลายข้อบังคับการเดินทางของไทยอันประกอบด้วย การยกเลิกมาตรการ Test & Go ตั้งแต่วันที่ 1 พ.ค. 22 และการบังคับใช้ Thailand Pass ที่อาจสิ้นสุดในเดือน มิ.ย. 22 หรือ 3Q22 น่าจะช่วยสนับสนุนตัวเลขผู้ป่วยต่างชาติให้ฟื้นตัวต่อเนื่อง ในที่ประชุมผู้บริหารไม่ได้ให้เป้าหมายการแต่ส่งสัญญาณว่าบริษัท เชื่อว่าตัวเลขผู้ป่วยต่างชาติมีแนวโน้มฟื้นตัวตลอดปี 2022

คาดการณ์กำไรแตะ 70% ของระดับก่อน Covid ในปี 2022

เราคาดว่ารายได้ผู้ป่วยต่างชาติจะกระโดดเพิ่ม 46% y-y ในปี 2022 และแตะ 70% ของระดับก่อน Covid พร้อมโอกาสสำหรับ Upside เพิ่มเติมจากการฟื้นตัวใน 1Q22 ที่อยู่ในระดับสูง รายได้ผู้ป่วยชาวไทยน่าจะโต 13% y-y ในปี 2022 และสูงกว่าระดับก่อน Covid อยู่ 14% นอกจากนี้ EBITDA margin น่าจะปรับตัวดีขึ้นจาก 22% ในปี 2021 เป็น 29% ในปี 2022 จากส่วนลดค่าบริการทางการแพทย์ที่ลดลงจาก 17% ในปี 2021 เป็น 14% ในปี 2022 (เทียบกับ 9.5% โดยเฉลี่ยในปี 2018-19) ในภาพรวมเราคาดว่ากำไรปกติจะเพิ่ม 114% เป็น 2.7 พัน ลบ. ในปี 2022 และ 70% ของระดับก่อน Covid ก่อนปรับขึ้นสูงกว่าระดับดังกล่าวในปี 2023

กำไรจะโตดี หุ่นมีการซื้อขายโดยมีส่วนลดเมื่อเทียบกับค่าเฉลี่ยในอดีต

เราประมาณการของเราและปรับการประเมินมูลค่าไปในปี 2023 พร้อมราคาเป้าหมายใหม่ที่ 205 บาท/หุ้น (DCF) ปัจจุบัน BH มีการซื้อขายในระดับการประเมินมูลค่าที่น่าสนใจ โดยอยู่ที่ 31x ของค่า 2023E P/E ซึ่งต่ำกว่าค่าเฉลี่ย 5 ปีย้อนหลังที่ 38x ในขณะที่เราคาดว่ากำไรปกติจะโตดีถึง 24% CAGR ในช่วงปี 2021-24



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	0.9	9.9	21.9
Relative to country (%)	5.4	12.9	17.6
Mkt cap (USD m)	3,737		
3m avg. daily turnover (USD m)	18.2		
Free float (%)	64		
Major shareholder	Dr. Satit Viddayakorn (18%)		
12m high/low (THB)	175.00/116.50		
Issued shares (m)	922.70		

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA

teerapol.udo@fssia.com
+66 2611 3535

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Investment thesis

We think BH's operations have already bottomed out. International patient revenue should continue to improve following the reopening of Thailand's borders.

We expect to see an improvement in Bumrungrad Health Network (BHN), which is the new business model that BHN and its partner hospitals have set up to jointly operate Centers of Excellence (CoE) in partnered hospitals. We believe there will be more CoE openings in partnered hospitals, especially hospitals under Principal Capital (PRINC TB, not rated), after Dr. Satit Viddayakorn, CEO and major shareholder of PRINC, acquired 23% of BH's shares in November 2020.

BH's efficient cost saving during the Covid pandemic should result in a higher EBITDA margin when revenue starts to recover.


Company profile

BH is a leading private hospital (580 licensed beds) in the premium segment.

www.bumrungrad.com

Principal activities (revenue, 2021)


- Thai patient revenue - 53.5 %
- International patient revenue - 46.1 %
- Other revenue - 0.5 %



Source: Bumrungrad Hospital

Major shareholders

- Dr. Satit Viddayakorn - 17.6 %
- Bangkok Insurance - 13.4 %
- Thai NVDR - 9.3 %
- UOB Kay Hian (Hong Kong) - 9.1 %
- Others - 50.6 %



Source: Bumrungrad Hospital

Catalysts

Key growth drivers include 1) the recovery of international patient numbers; 2) its new business model, "Bumrungrad Health Network", which should enable BH to capture the middle-class patient segment; and 3) its vital life business (Wellness) which has a high margin compared to traditional healthcare.

Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.

Event calendar

Date	Event
Aug 2022	2Q22 results announcement

Key assumptions

	2022E	2023E	2024E
	(%)	(%)	(%)
OPD volume growth	32	10	4
OPD revenue / patient growth	3	15	3
IPD volume growth	16	11	4
IPD revenue / patient growth	14	10	3

Source: FSSIA estimates

Earnings sensitivity

- For every 1% increase in patient volume, we project 2023 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2023 earnings to rise by 4%, and vice versa, all else being equal.

Source: FSSIA estimates

Recap: 1Q22 results review

BH reported a core profit of THB725m (+640% y-y, +9% q-q) in 1Q22, beating Bloomberg's consensus estimate by 10%. Its 1Q22 core profit hit a record high since the beginning of the pandemic at 67% of the pre-Covid level.

Revenue grew 6% q-q, while international patient revenue grew by 28% q-q and recovered to 73% of the pre-Covid level, up from 61% in 4Q21. Thai patient revenue dropped slightly by 7% q-q due to the seasonal effect but was still 19% higher than the pre-Covid level. As a result, the revenue contribution from Thai patients was 45% and international patients 55%.


The EBITDA margin jumped to 28% from 16% in 1Q21, down slightly from 29% in 4Q21 due to 3% q-q higher SG&A. Interest expenses declined from THB26m in 4Q21 to THB2m in 1Q22 after BH redeemed its debentures.

1Q22 core profit amounted to 27% of our 2022 core profit forecast of THB2.7b.


Exhibit 1: 1Q22 results review

	1Q21	2Q21	3Q21	4Q21	1Q22	----- Change -----		2022E
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)
Sales	2,655	2,994	2,915	3,896	4,118	6	55	15,969
COGS (incl. depreciation)	(1,748)	(1,905)	(1,814)	(2,264)	(2,394)	6	37	(9,107)
Gross profit	908	1,089	1,101	1,632	1,724	6	90	6,862
SG&A	(812)	(835)	(813)	(836)	(865)	3	7	(3,585)
Operating profit	96	254	288	796	859	8	798	3,277
Net other income	23	21	74	25	34	35	48	85
Interest income	21	17	16	15	11	(24)	(46)	50
Interest expense	(31)	(31)	(31)	(26)	(2)	(94)	(95)	(9)
Pretax profit	109	261	346	811	903	11	730	3,403
Income Tax	(12)	(38)	(39)	(127)	(168)	32	1,313	(647)
Associates	0	(10)	(2)	(0)	(0)	(49)	(102)	(13)
Minority interest	1	(1)	(7)	(17)	(10)	(39)	(1,158)	(13)
Core profit	98	212	298	667	725	9	640	2,731
Extraordinaries, GW & FX	(7)	5	(2)	(55)	(0)	(99)	(94)	0
Reported net profit	91	216	296	612	725	18	696	2,731
Outstanding shares (m)	795	795	795	795	795	0	0	795
Core EPS (THB)	0.12	0.27	0.37	0.84	0.91	9	640	3.43
EPS (THB)	0.11	0.27	0.37	0.77	0.91	18	695	3.43
COGS (excl. depreciation)	1,449	1,609	1,521	1,972	2,117	7	46	7,901
Depreciation	298	296	294	292	277	(5)	(7)	1,206
EBITDA	417	571	655	1,114	1,170	5	180	4,568
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)
Gross margin	34	36	38	42	42	(0)	8	43
SG&A/Revenue	31	28	28	21	21	(0)	(10)	22
EBITDA margin	16	19	22	29	28	(0)	13	29
Net profit margin	3	7	10	16	18	2	14	17
Operating stats	(y-y %)	(y-y %)	(y-y %)	(y-y %)	(y-y %)			
Hospital revenue growth	(35)	23	0	33	55			
OPD revenue growth	(34)	23	(7)	na	na			
IPD revenue growth	(37)	23	9	na	na			
International patient revenue growth	(54)	19	(4)	50	87			
Thai patient revenue growth	1	27	4	20	28			


Sources: BH; FSSIA estimates

Exhibit 2: International patient revenue, quarterly


Source: BH

Exhibit 3: Thai patient revenue, quarterly


Source: BH

Exhibit 4: International patient revenue


Sources: BH; FSSIA estimates

Exhibit 5: Thai patient revenue

Sources: BH; FSSIA estimates

Exhibit 6: EBITDA margin improvement trend

Sources: BH; FSSIA estimates

Exhibit 7: Discount rate development


Sources: BH; FSSIA's compilation

Exhibit 8: DCF valuation

Cost of equity assumptions (%)		Cost of debt assumptions (%)	
Risk-free rate	3.0	Pre-tax cost of debt	3.5
Market risk premium	8.0	Marginal tax rate	20.0
Stock beta	0.7		
Cost of equity, Ke	8.6	Net cost of debt, Kd	2.8
Weight applied	87.0	Weight applied	13.0
WACC	7.8		
DCF valuation estimate	(THB b)	(THB/share)	Comments
NPV	54.7	59.2	WACC 7.8%, Risk-free rate 3%, Risk premium 8%
Terminal value	125.5	136.0	Terminal growth 3%
Cash & liquid assets	9.4	10.2	At end-2023E
Investments	0.0	0.0	At end-2023E
Debt	(0.1)	(0.1)	At end-2023E
Minorities	(0.4)	(0.4)	At end-2023E
Residual ordinary equity	189.1	205.0	


Source: FSSIA estimates

Exhibit 9: One-year forward rolling P/E band



Sources: Bloomberg; FSSIA estimates

Exhibit 10: One-year forward rolling P/BV band



Sources: Bloomberg; FSSIA estimates

Exhibit 11: Peer comparisons as of 6 May-22

Company	BBG	Rec	Share price			Market	PE		ROE		PBV		EV/EBITDA	
			Current	Target	Upside	Cap	22E	23E	22E	23E	22E	23E	22E	23E
			(LCY)	(LCY)	(%)	(USD m)	(x)	(x)	(%)	(%)	(x)	(x)	(x)	(x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	24.80	31.00	25.0	11,474	39.0	31.4	11.8	13.9	4.5	4.2	19.9	16.8
Bumrungrad Hospital	BH TB	BUY	161.50	205.00	26.9	3,737	47.1	30.6	15.7	23.0	7.4	6.7	27.3	19.1
Bangkok Chain Hospital	BCH TB	BUY	21.20	28.50	34.4	1,539	11.4	26.7	33.7	13.7	3.6	3.7	7.3	13.6
Chularat Hospital	CHG TB	BUY	3.66	4.70	28.4	1,172	13.3	27.7	37.8	17.7	4.8	5.0	8.9	16.4
Praram 9 Hospital	PR9 TB	BUY	13.40	16.50	23.1	307	25.7	22.2	9.3	10.2	2.3	2.2	11.1	9.8
Thonburi Healthcare Group	THG TB	HOLD	58.00	32.50	(44.0)	1,431	54.6	78.9	9.8	6.7	5.3	5.3	26.2	29.9
Vibhavadi Medical Center	VIBHA TB	BUY	2.52	3.20	27.0	996	32.7	31.6	8.1	7.3	2.3	2.3	29.3	26.5
Ramkhamhaeng Hospital	RAM TB	BUY	48.75	56.00	14.9	1,703	26.3	26.1	12.5	11.8	3.2	3.0	22.8	22.0
Rajthanee Hospital	RJH TB	n/a	33.75	n/a	n/a	294	15.6	23.0	33.5	21.8	6.8	5.0	10.4	14.9
Ekachai Medical Care	EKH TB	n/a	7.40	n/a	n/a	134	25.5	25.0	15.9	14.4	5.3	3.8	14.6	13.7
Thailand average						22,788	29.1	32.3	18.8	14.0	4.5	4.1	17.8	18.3
Regional														
Ramsay Health Care	RHC AU	n/a	77.80	n/a	n/a	12,534	54.7	31.6	8.7	13.7	4.4	4.4	13.7	11.2
Ihh Healthcare Bhd	IHH SP	n/a	2.06	n/a	n/a	12,980	34.3	30.1	6.8	7.3	2.3	2.3	15.3	14.2
Ryman Healthcare	RYM NZ	n/a	8.82	n/a	n/a	2,778	19.0	14.0	7.5	8.9	1.3	1.3	19.0	16.2
Apollo Hospitals Enterprise	APHS IN	n/a	3,827	n/a	n/a	7,147	59.2	46.4	18.7	18.7	9.7	9.7	25.3	21.6
Kpj Healthcare Berhad	KPJ MK	n/a	0.92	n/a	n/a	913	27.9	20.9	6.6	8.6	1.7	1.7	11.4	10.3
Raffles Medical Group	RFMD SP	n/a	1.21	n/a	n/a	1,550	30.5	28.3	7.5	7.7	2.2	2.2	14.9	14.2
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,530	n/a	n/a	2,485	34.2	31.0	18.9	19.3	6.2	6.2	20.9	18.7
Aier Eye Hospital Group	300015 CH	n/a	36.18	n/a	n/a	29,423	66.1	50.5	22.0	23.6	14.0	14.0	38.2	30.1
Regional average						69,810	40.8	31.6	12.1	13.5	5.2	5.2	19.8	17.1
Overall average						92,598	34.3	32.0	15.8	13.8	4.9	4.6	18.7	17.7

Sources: Bloomberg; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Profit and Loss (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Revenue	12,362	12,460	15,969	19,841	21,249
Cost of goods sold	(6,457)	(6,551)	(7,901)	(9,519)	(10,088)
Gross profit	5,905	5,909	8,068	10,322	11,161
Other operating income	-	-	-	-	-
Operating costs	(3,394)	(3,296)	(3,585)	(4,058)	(4,282)
Operating EBITDA	2,511	2,613	4,483	6,264	6,879
Depreciation	(1,220)	(1,180)	(1,206)	(1,233)	(1,281)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	1,291	1,434	3,277	5,032	5,598
Net financing costs	0	(51)	41	98	141
Associates	(2)	(12)	(13)	(14)	(14)
Recurring non-operating income	75	132	72	74	76
Non-recurring items	5	(58)	0	0	0
Profit before tax	1,371	1,456	3,390	5,203	5,815
Tax	(150)	(216)	(647)	(991)	(1,166)
Profit after tax	1,221	1,240	2,744	4,212	4,649
Minority interests	(17)	(24)	(13)	(13)	(13)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	1,204	1,216	2,731	4,199	4,636
Non-recurring items & goodwill (net)	(5)	58	0	0	0
Recurring net profit	1,199	1,274	2,731	4,199	4,636
Per share (THB)					
Recurring EPS *	1.51	1.60	3.43	5.28	5.83
Reported EPS	1.51	1.53	3.43	5.28	5.83
DPS	3.20	3.20	3.20	3.20	3.17
Diluted shares (used to calculate per share data)	796	796	796	796	796
Growth					
Revenue (%)	(33.1)	0.8	28.2	24.2	7.1
Operating EBITDA (%)	(56.8)	4.1	71.5	39.7	9.8
Operating EBIT (%)	(71.8)	11.1	128.6	53.5	11.3
Recurring EPS (%)	(71.7)	6.2	114.4	53.8	10.4
Reported EPS (%)	(70.6)	1.0	124.7	53.8	10.4
Operating performance					
Gross margin inc. depreciation (%)	37.9	38.0	43.0	45.8	46.5
Gross margin of key business (%)	37.9	38.0	43.0	45.8	46.5
Operating EBITDA margin (%)	20.3	21.0	28.1	31.6	32.4
Operating EBIT margin (%)	10.4	11.5	20.5	25.4	26.3
Net margin (%)	9.7	10.2	17.1	21.2	21.8
Effective tax rate (%)	10.9	14.1	19.0	19.0	20.0
Dividend payout on recurring profit (%)	212.1	199.7	93.2	60.6	54.3
Interest cover (X)	(5,021.5)	30.7	(81.1)	(52.1)	(40.2)
Inventory days	18.1	17.7	16.7	16.7	17.7
Debtor days	73.1	53.7	29.7	19.2	16.2
Creditor days	44.5	42.0	38.5	36.4	38.7
Operating ROIC (%)	8.7	9.7	22.3	36.6	43.3
ROIC (%)	8.3	10.0	21.9	35.6	42.0
ROE (%)	6.2	7.1	15.7	23.0	23.0
ROA (%)	4.8	6.0	12.9	18.5	18.5
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)					
Thai patient revenue	5,924	6,661	7,527	7,678	7,831
International patient revenue	6,392	5,743	8,387	12,110	13,365
Other revenue	47	56	55	53	52

Sources: Bumrungrad Hospital; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Cash Flow (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Recurring net profit	1,199	1,274	2,731	4,199	4,636
Depreciation	1,220	1,180	1,206	1,233	1,281
Associates & minorities	-	-	-	-	-
Other non-cash items	(370)	318	13	13	13
Change in working capital	(172)	897	424	589	141
Cash flow from operations	1,877	3,668	4,374	6,034	6,071
Capex - maintenance	(1,073)	(928)	(1,086)	(794)	(850)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	1,320	74	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	246	(853)	(1,086)	(794)	(850)
Dividends paid	(2,544)	(2,545)	(2,546)	(2,546)	(2,520)
Equity finance	230	0	0	0	0
Debt finance	93	(2,516)	0	0	0
Other financing cash flows	(254)	44	0	0	0
Cash flow from financing	(2,476)	(5,017)	(2,546)	(2,546)	(2,520)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	(352)	(2,203)	741	2,694	2,701
Free cash flow to firm (FCFF)	2,251.07	2,934.46	3,296.54	5,249.07	5,229.88
Free cash flow to equity (FCFE)	1,961.78	342.35	3,287.65	5,240.18	5,220.99
Per share (THB)					
FCFF per share	2.44	3.18	3.57	5.69	5.67
FCFE per share	2.13	0.37	3.56	5.68	5.66
Recurring cash flow per share	2.57	3.48	4.96	6.84	7.45
Balance Sheet (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Tangible fixed assets (gross)	24,861	25,744	26,830	27,624	28,474
Less: Accumulated depreciation	(12,337)	(13,425)	(14,631)	(15,864)	(17,146)
Tangible fixed assets (net)	12,525	12,319	12,199	11,760	11,328
Intangible fixed assets (net)	64	71	71	71	71
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	76	1	1	1	1
Cash & equivalents	8,138	5,936	6,677	9,371	12,072
A/C receivable	2,206	1,461	1,142	943	943
Inventories	309	328	395	476	504
Other current assets	148	338	307	382	409
Current assets	10,801	8,062	8,521	11,171	13,928
Other assets	757	404	404	404	404
Total assets	24,222	20,857	21,195	23,407	25,732
Common equity	18,532	17,286	17,471	19,124	21,240
Minorities etc.	305	332	344	357	370
Total shareholders' equity	18,837	17,618	17,815	19,481	21,610
Long term debt	2,587	71	71	71	71
Other long-term liabilities	914	924	924	924	924
Long-term liabilities	3,501	995	995	995	995
A/C payable	704	805	862	1,038	1,100
Short term debt	0	0	0	0	0
Other current liabilities	1,179	1,439	1,524	1,893	2,027
Current liabilities	1,884	2,244	2,385	2,931	3,127
Total liabilities and shareholders' equity	24,222	20,857	21,195	23,407	25,732
Net working capital	779	(117)	(541)	(1,130)	(1,271)
Invested capital	14,200	12,677	12,134	11,105	10,533
* Includes convertibles and preferred stock which is being treated as debt					
Per share (THB)					
Book value per share	23.29	21.72	21.95	24.03	26.69
Tangible book value per share	23.21	21.63	21.87	23.94	26.60
Financial strength					
Net debt/equity (%)	(29.5)	(33.3)	(37.1)	(47.7)	(55.5)
Net debt/total assets (%)	(22.9)	(28.1)	(31.2)	(39.7)	(46.6)
Current ratio (x)	5.7	3.6	3.6	3.8	4.5
CF interest cover (x)	(7,210.9)	7.7	(78.6)	(52.5)	(36.0)
Valuation	2020	2021	2022E	2023E	2024E
Recurring P/E (x) *	107.1	100.9	47.1	30.6	27.7
Recurring P/E @ target price (x) *	136.0	128.0	59.7	38.8	35.2
Reported P/E (x)	106.7	105.7	47.1	30.6	27.7
Dividend yield (%)	2.0	2.0	2.0	2.0	2.0
Price/book (x)	6.9	7.4	7.4	6.7	6.1
Price/tangible book (x)	7.0	7.5	7.4	6.7	6.1
EV/EBITDA (x) **	49.1	47.1	27.3	19.1	17.0
EV/EBITDA @ target price (x) **	62.9	60.3	35.0	24.6	22.0
EV/invested capital (x)	8.7	9.7	10.1	10.8	11.1
* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income					

Sources: Bumrungrad Hospital; FSSIA estimates

Corporate Governance report of Thai listed companies 2020

EXCELLENT LEVEL										
AAV	ADVANC	AF	AIRA	AKP	AKR	ALT	AMA	AMATA	AMATAV	ANAN
AOT	AP	ARIP	ARROW	ASP	BAFS	BANPU	BAY	BCP	BCPG	BDMS
BEC	BEM	BGRIM	BIZ	BKI	BLA	BOL	BPP	BRR	BTS	BWG
CENTEL	CFRESH	CHEWA	CHO	CIMBT	CK	CKP	CM	CNT	COL	COMAN
COTTO	CPALL	CPF	CPI	CPN	CSS	DELTA	DEMCO	DRT	DTAC	DTC
DV8	EA	EASTW	ECF	ECL	EGCO	EPG	ETE	FNS	FPI	FPT
FSMART	GBX	GC	GCAP	GEL	GFPT	GGC	GPSC	GRAMMY	GUNKUL	HANA
HARN	HMPRO	ICC	ICHI	III	ILINK	INTUCH	IRPC	IVL	JKN	JSP
JWD	K	KBANK	KCE	KKP	KSL	KTB	KTC	LANNA	LH	LHFG
LIT	LPN	MAKRO	MALEE	MBK	MBKET	MC	MCOT	METCO	MFEC	MINT
MONO	MOONG	MSC	MTC	NCH	NCL	NEP	NKI	NOBLE	NSI	NVD
NYT	OISHI	ORI	OTO	PAP	PCSGH	PDJ	PG	PHOL	PLANB	PLANET
PLAT	PORT	PPS	PR9	PREB	PRG	PRM	PSH	PSL	PTG	PTT
PTTEP	PTTGC	PYLON	Q-CON	QH	QTC	RATCH	RS	S	S & J	SAAM
SABINA	SAMART	SAMTEL	SAT	SC	SCB	SCC	SCCC	SCG	SCN	SDC
SEAFCO	SEOIL	SE-ED	SELIC	SENA	SIRI	SIS	SITHAI	SMK	SMPC	SNC
SONIC	SORKON	SPALI	SPI	SPRC	SPVI	SSSC	SST	STA	SUSCO	SUTHA
SVI	SYMC	SYNTEC	TACC	TASCO	TCAP	TFMAMA	THANA	THANI	THCOM	THG
THIP	THRE	THREL	TIP	TIPCO	TISCO	TK	TKT	TTB	TMILL	TNDT
TNL	TOA	TOP	TPBI	TQM	TRC	TSC	TSR	TSTE	TSTH	TTA
TTCL	TTW	TU	TVD	TVI	TVO	TWPC	U	UAC	UBIS	UV
VGI	VIH	WACOAL	WAVE	WHA	WHAUP	WICE	WINNER	TRUE		
VERY GOOD LEVEL										
2S	ABM	ACE	ACG	ADB	AEC	AEONTS	AGE	AH	AHC	AIT
ALLA	AMANAHA	AMARIN	APCO	APCS	APURE	AQUA	ASAP	ASEFA	ASIA	ASIAN
ASIMAR	ASK	ASN	ATP30	AUCT	AWC	AYUD	B	BA	BAM	BBL
BFIT	BGC	BJC	BJCHI	BROOK	BTW	CBG	CEN	CGH	CHARAN	CHAYO
CHG	CHOTI	CHOW	CI	CIG	CMC	COLOR	COM7	CPL	CRC	CRD
CSC	CSP	CWT	DCC	DCON	DDD	DOD	DOHOME	EASON	EE	ERW
ESTAR	FE	FLOYD	FN	FORTH	FSS	FTE	FVC	GENCO	GJS	GL
GLAND	GLOBAL	GLOCON	GPI	GULF	GYT	HPT	HTC	ICN	IFS	ILM
IMH	INET	INSURE	IRC	IRCP	IT	ITD	ITEL	J	JAS	JCK
JCKH	JMART	JMT	KBS	KCAR	KGI	KIAT	KOOL	KTIS	KWC	KWM
L&E	LALIN	LDC	LHK	LOXLEY	LPH	LRH	LST	M	MACO	MAJOR
MBAX	MEGA	META	MFC	MGT	MILL	MITSI	MK	MODERN	MTI	MVP
NETBAY	NEX	NINE	NTV	NWR	OCC	OGC	OSP	PATO	PB	PDG
PDI	PICO	PIMO	PJW	PL	PM	PPP	PRIN	PRINC	PSTC	PT
QLT	RCL	RICHY	RML	RPC	RWI	S11	SALEE	SAMCO	SANKO	SAPPE
SAWAD	SCI	SCP	SE	SEG	SFP	SGF	SHR	SIAM	SINGER	SKE
SKR	SKY	SMIT	SMT	SNP	SPA	SPC	SPCG	SR	SRICHA	SSC
SSF	STANLY	STI	STPI	SUC	SUN	SYNEX	T	TAE	TAKUNI	TBSP
TCC	TCMC	TEAM	TEAMG	TFG	TIGER	TITLE	TKN	TKS	TM	TMC
TMD	TMI	TMT	TNITY	TNP	TNR	TOG	TPA	TPAC	TPCORP	TPOLY
TPS	TRITN	TRT	TRU	TSE	TVT	TWP	UEC	UMI	UOBKH	UP
UPF	UPOIC	UT	UTP	UWC	VL	VNT	VPO	WIIK	WP	XO
YUASA	ZEN	ZIGA	ZMICO							
GOOD LEVEL										
7UP	A	ABICO	AJ	ALL	ALUCON	AMC	APP	ARIN	AS	AU
B52	BC	BCH	BEAUTY	BGT	BH	BIG	BKD	BLAND	BM	BR
BROCK	BSBM	BSM	BTNC	CAZ	CCP	CGD	CITY	CMAN	CMO	CMR
CPT	CPW	CRANE	CSR	D	EKH	EP	ESSO	FMT	GIFT	GREEN
GSC	GTB	HTECH	HUMAN	IHL	INOX	INSET	IP	JTS	JUBILE	KASET
KCM	KKC	KUMWEL	KUN	KWG	KYE	LEE	MATCH	MATI	M-CHAI	MCS
MDX	MJD	MM	MORE	NC	NDR	NER	NFC	NNCL	NPK	NUSA
OCEAN	PAF	PF	PK	PLE	PMTA	POST	PPM	PRAKIT	PRECHA	PRIME
PROUD	PTL	RBF	RCI	RJH	ROJNA	RP	RPH	RSP	SF	SFLEX
SGP	SISB	SKN	SLP	SMART	SOLAR	SPG	SQ	SSP	STARK	STC
SUPER	SVOA	TC	TCCC	THMUI	TIW	TNH	TOPP	TPCH	TIPIP	TPLAS
TTI	TYCN	UKEM	UMS	VCOM	VRANDA	WIN	WORK	WPH		
Description								Score Range		
Excellent								90-100		
Very Good								80-89		
Good								70-79		

Disclaimer:

The disclosure of the survey results of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey results may be changed after that date. FSS International Investment Advisory Company Limited does not confirm nor certify the accuracy of such survey results.

* CGR scoring should be considered with news regarding wrong doing of the company or director or executive of the company such unfair practice on securities trading, fraud, and corruption SEC imposed a civil sanction against insider trading of director and executive; ** delisted

Source: Thai Institute of Directors Association (IOD); FSSIA's compilation

Anti-corruption Progress Indicator 2020

CERTIFIED										
2S	ADVANC	AI	AIE	AIRA	AKP	AMA	AMANA	AP	AQUA	ARROW
ASK	ASP	AYUD	B	BAFS	BANPU	BAY	BBL	BCH	BCP	BCPG
BGC	BGRIM	BJCHI	BKI	BLA	BPP	BROOK	BRR	BSBM	BTS	BWG
CEN	CENTEL	CFRESH	CGH	CHEWA	CHOTI	CHOW	CIG	CIMBT	CM	CMC
COL	COM7	CPALL	CPF	CPI	CPN	CSC	DCC	DELTA	DEMCO	DIMET
DRT	DTAC	DTC	EASTW	ECL	EGCO	FE	FNS	FPI	FPT	FSS
FTE	GBX	GC	GCAP	GEL	GFPT	GGC	GJS	GPSC	GSTEEL	GUNKUL
HANA	HARN	HMPRO	HTC	ICC	ICHI	IFS	INET	INSURE	INTUCH	IRPC
ITEL	IVL	K	KASET	KBANK	KBS	KCAR	KCE	KGI	KKP	KSL
KTB	KTC	KWC	L&E	LANNA	LHFG	LHK	LPN	LRH	M	MAKRO
MALEE	MBAX	MBK	MBKET	MC	MCOT	MFC	MFEC	MINT	MONO	MOONG
MPG	MSC	MTC	MTI	NBC	NEP	NINE	NKI	NMG	NNCL	NSI
NWR	OCC	OCEAN	OGC	ORI	PAP	PATO	PB	PCSGH	PDG	PDI
PDJ	PE	PG	PHOL	PL	PLANB	PLANET	PLAT	PM	PPP	PPPM
PPS	PREB	PRG	PRINC	PRM	PSH	PSL	PSTC	PT	PTG	PTT
PTTEP	PTTGC	PYLON	Q-CON	QH	QLT	QTC	RATCH	RML	RWI	S & J
SABINA	SAT	SC	SCB	SCC	SCCC	SCG	SCN	SEAOL	SE-ED	SELIC
SENA	SGP	SIRI	SITHAI	SMIT	SMK	SMPC	SNC	SNP	SORKON	SPACK
SPC	SPI	SPRC	SRICHA	SSF	SSSC	SST	STA	SUSCO	SVI	SYNTEC
TAE	TAKUNI	TASCO	TBSP	TCAP	TCMC	TFG	TFI	TFMAMA	THANI	THCOM
THIP	THRE	THREL	TIP	TIPCO	TISCO	TKT	TTB	TMD	TMILL	TMT
TNITY	TNL	TNP	TNR	TOG	TOP	TPA	TPCORP	TPP	TRU	TSC
TSTH	TTCL	TU	TVD	TVI	TVO	TWPC	U	UBIS	UEC	UKEM
UOBKH	UWC	VGI	VIH	VNT	WACOAL	WHA	WHAUP	WICE	WIJK	XO
ZEN	TRUE									
DECLARED										
7UP	ABICO	AF	ALT	AMARIN	AMATA	AMATAV	ANAN	APURE	B52	BKD
BM	BROCK	BUI	CHO	CI	COTTO	DDD	EA	EFORL	EP	ERW
ESTAR	ETE	EVER	FSMART	GPI	ILINK	IRC	J	JKN	JMART	JMT
JSP	JTS	KWG	LDC	MAJOR	META	NCL	NOBLE	NOK	PK	PLE
ROJNA	SAAM	SAPPE	SCI	SE	SHANG	SINGER	SKR	SPALI	SSP	STANLY
SUPER	SYNEX	THAI	TKS	TOPP	TRITN	TTA	UPF	UV	WIN	ZIGA

Level	
Certified	This level indicates practical participation with thoroughly examination in relation to the recommended procedures from the audit committee or the SEC's certified auditor, being a certified member of Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) or already passed examination to ensure independence from external parties.
Declared	This level indicates determination to participate in the Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC)

Disclaimer:

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, FSS International Investment Advisory Company Limited does not confirm, verify, or certify the accuracy and completeness of the assessment results.

Note: Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of June 24, 2019) are categorised into: 1) companies that have declared their intention to join CAC, and; 2) companies certified by CAC.

Source: The Securities and Exchange Commission, Thailand; * FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSS makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSS has no intention to solicit investors to buy or sell any security in this report. In addition, FSS does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Bumrungrad Hospital	BH TB	THB 161.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Bangkok Dusit Medical Services	BDMS TB	THB 24.80	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bangkok Chain Hospital	BCH TB	THB 21.20	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Chularat Hospital	CHG TB	THB 3.66	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Praram 9 Hospital	PR9 TB	THB 13.40	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Thonburi Healthcare Group	THG TB	THB 58.00	HOLD	Downside risks to our DCF-based target price include 1) weak patient volume following the economic slowdown; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected expenses from new hospitals. Upside risk is big-lot sales of Jin Wellbeing County units.
Vibhavadi Medical Center	VIBHA TB	THB 2.52	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Ramkhamhaeng Hospital	RAM TB	THB 48.75	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited

FSSIA may incorporate the recommendations and target prices of companies currently covered by FSS Research into equity research reports, denoted by an 'FSS' before the recommendation. FSS Research is part of Finansia Syrus Securities Public Company Limited, which is the parent company of FSSIA.

All share prices are as at market close on 06-May-2022 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as $(\text{target price}^* - \text{current price}) / \text{current price}$.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.